/ Kōrerorero blog / 10 May 2021 / Katie Hickmer
...........................................................
From a Kiwi start-up to a global player in medical device, Aroa Biosurgery is focused on improving the rate and quality of healing in complex wounds and soft tissue reconstruction.
Brian Ward is the CEO and Founder of Aroa, founded in 2008 and as of June 2020, the company was listed on the ASX through an IPO which valued Aroa at A$225 million. Brian was also recently recognised as one of the top healthcare technology company CEOs for 2021, ranked at #26.
...........................................................
Our idea came from observing the emergence of regenerative medicine as a new field of medicine. There was a growing interest in tissue derived scaffolds for accelerating healing in patients with hard to heal wounds, and the large unmet clinical need for high quality products which were widely accessible to patients. After evaluating a wide range of tissues, I identified ovine forestomach matrix as a potential building block for a wide range of medical tissue regeneration products.
Thankfully, I didn’t know how hard it would be to raise funds for a life science company during the first few years before we had meaningful sales. Investors were generally very sceptical and we also had to contend with the GFC and the subsequent fallout. It was a nuclear winter for a couple of years. But we found our way through and raising money seems to get easier as you get larger.
Immediately before I started the company I was deeply immersed in the New Zealand biotech industry as the CEO of NZBio. I met people who had previously raised money and that was a big leg up for the initial seed round. As we’ve built the company I’ve learnt a lot from the experienced Directors, Investors and various service providers.
I’ve always admired technology companies that make products which genuinely benefit people’s lives, and at the same time provide interesting work for employees and meet shareholder expectations. Fisher & Paykel Health Care is a great local example.
Persistence is the biggest contributor to success.
...........................................................
Our Aspire NZ Seed Fund is a generalist early-stage investment fund that invests in Kiwi start-up companies with a focus on four technology areas; Software, Health-tech, Deep-tech and Agri-tech. Aroa Biosurgery fits within the health-tech area/sector.
...........................................................
This is our 7th Kōrerorero of the series.
/ News
30 May 2022
Elevate is committing $30m into Blackbird Ventures’ second New Zealand fund which is targeting a…
/ blog-insights
24 May 2022
A comprehensive list of resources, support, and networking opportunities for women entrepreneurs in…
/ General publications
2 May 2022
In collaboration with PWC and AANZ, we share insights on growing a sustainable ecosystem